Perception of prescription drug monitoring programs as a prevention tool in primary medical care

Amie J. Goodin, Joshua D. Brown, Chris Delcher, Patricia R. Freeman, Jeffery Talbert, Stephen G Henry, Dikea Roussos-Ross

Research output: Contribution to journalArticle

Abstract

Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

Original languageEnglish (US)
JournalResearch in Social and Administrative Pharmacy
DOIs
StatePublished - Jan 1 2019

Fingerprint

Prescription Drugs
Drug Monitoring
Primary Care Physicians
Health care
Primary Health Care
Monitoring
Program Evaluation
Prescription Drug Diversion
Substance-Related Disorders
Prescription Drug Misuse
Patient Care Team
Chi-Square Distribution
Primary Prevention

Keywords

  • Controlled substance use in pregnancy
  • Neonatal abstinence syndrome
  • Opioid analgesics
  • Prescription drug monitoring programs

ASJC Scopus subject areas

  • Pharmacy
  • Pharmaceutical Science

Cite this

Perception of prescription drug monitoring programs as a prevention tool in primary medical care. / Goodin, Amie J.; Brown, Joshua D.; Delcher, Chris; Freeman, Patricia R.; Talbert, Jeffery; Henry, Stephen G; Roussos-Ross, Dikea.

In: Research in Social and Administrative Pharmacy, 01.01.2019.

Research output: Contribution to journalArticle

Goodin, Amie J. ; Brown, Joshua D. ; Delcher, Chris ; Freeman, Patricia R. ; Talbert, Jeffery ; Henry, Stephen G ; Roussos-Ross, Dikea. / Perception of prescription drug monitoring programs as a prevention tool in primary medical care. In: Research in Social and Administrative Pharmacy. 2019.
@article{437cedc80f9349b894858e9e560543b5,
title = "Perception of prescription drug monitoring programs as a prevention tool in primary medical care",
abstract = "Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1{\%} OB/GYN vs. 83.7{\%} PCP “agree positive impact”; Kentucky: 45.0{\%} OB/GYN vs. 68.5{\%} PCP “effective”. California: 73.2{\%} OB/GYN vs. 86.4{\%} PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.",
keywords = "Controlled substance use in pregnancy, Neonatal abstinence syndrome, Opioid analgesics, Prescription drug monitoring programs",
author = "Goodin, {Amie J.} and Brown, {Joshua D.} and Chris Delcher and Freeman, {Patricia R.} and Jeffery Talbert and Henry, {Stephen G} and Dikea Roussos-Ross",
year = "2019",
month = "1",
day = "1",
doi = "10.1016/j.sapharm.2019.03.012",
language = "English (US)",
journal = "Research in Social and Administrative Pharmacy",
issn = "1551-7411",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Perception of prescription drug monitoring programs as a prevention tool in primary medical care

AU - Goodin, Amie J.

AU - Brown, Joshua D.

AU - Delcher, Chris

AU - Freeman, Patricia R.

AU - Talbert, Jeffery

AU - Henry, Stephen G

AU - Roussos-Ross, Dikea

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

AB - Background: Prescription drug monitoring programs (PDMPs) are primary prevention tools to reduce substance use disorders (SUD) and sequelae. Evidence regarding perceptions of PDMPs from different primary care providers, which may impact PDMP utilization for women, is unavailable. Objective: To examine perceived PDMP effectiveness among obstetrician-gynecologists (OB/GYNs) compared to primary care physicians (PCPs). Methods: Independent surveys of PDMP users in Florida, Kentucky, and California were evaluated based on a Likert-type item to assess perception of PDMP effectiveness in reducing prescription drug abuse and diversion. Response distributions of OB/GYNs versus PCPs were compared using chi-square tests. Results: In Florida, there were 41 OB/GYN and 511 PCP respondents; Kentucky, 46 OB/GYNs and 265 PCPs; and California, 41 OB/GYNs and 162 PCPs. In each state OB/GYNs viewed PDMPs as less effective, positive, or useful compared to PCPs (p ≤ 0.01, all states): Florida: 64.1% OB/GYN vs. 83.7% PCP “agree positive impact”; Kentucky: 45.0% OB/GYN vs. 68.5% PCP “effective”. California: 73.2% OB/GYN vs. 86.4% PCP “useful”. Conclusions: These results suggest OB/GYNs view their state's PDMP as less effective than do PCPs, which may present barriers to PDMP utilization and decrease opportunities for SUD interventions. Engagement of all healthcare team members is needed to inform future strategies and policies to increase PDMP effectiveness.

KW - Controlled substance use in pregnancy

KW - Neonatal abstinence syndrome

KW - Opioid analgesics

KW - Prescription drug monitoring programs

UR - http://www.scopus.com/inward/record.url?scp=85063446987&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85063446987&partnerID=8YFLogxK

U2 - 10.1016/j.sapharm.2019.03.012

DO - 10.1016/j.sapharm.2019.03.012

M3 - Article

AN - SCOPUS:85063446987

JO - Research in Social and Administrative Pharmacy

JF - Research in Social and Administrative Pharmacy

SN - 1551-7411

ER -